Oct. 23 at 2:33 PM
$SLNO Pricing: The company and analysts confirm Vykat XR is priced at roughly
$466,000 per patient per year in the U.S. (at
$5.92/mg, mean 61 kg).
Patient population (TAM): U.S. diagnosed PWS population spans ~10,000; EU5 (main European markets) add ~9,000.
Gross TAM: 19,000 x
$466,000 =
$8.X.85 billion maximum annual sales if every eligible patient is treated at full U.S. price.
Serviceable Addressable Market (SAM): Real-world adoption is lower—assume 25% penetration by 2028, or ~4,750 patients worldwide.
Peak sales calculation: 4,750 x
$466,000 =
$2.X.21 billion in gross peak annual sales.
Discount for net price: Real net after discounts/rebates likely 80% of list, so
$2.X.21B x 0.8 =
$1.X.77 billion in net peak annual sales.
Analyst consensus check: Most analysts (Stifel, Visible Alpha, Investing) project U.S. peak sales from
$1.X.1B to
$2B, worldwide
$2.X.0–2.8B, which brackets this estimate.
